$27.55▲ 2.70 (10.87%)
Real-time prices · US MarketsConsensus analyst target of $52.05 is 89% above current price.
currently unprofitable (-91% margin).
Quality
2.2
Health
5.4
Growth
3.4
Valuation
9
Sentiment
8.3
Analyst Target
$52.05
▲ +88.9% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
28.5×
next 12 months est.
Market Cap
$2.7B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-90.9%
net profit margin
Gross Margin
-28.1%
revenue minus COGS
ROE
—
return on equity
Beta
0.38
vs S&P 500
52-Week Range
$18 — $42
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Ultragenyx Pharmaceutical Inc. right now?
Ultragenyx Pharmaceutical Inc.'s Q·Score is 5.4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $52.05 is 89% above current price. Key area to monitor: currently unprofitable (-91% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RARE?
The consensus price target for RARE is $52.05, based on ratings from 19 Wall Street analysts. This is 88.9% above the current price of $27.55. Price targets are forward-looking estimates and not guarantees of future performance.
Is RARE overvalued or undervalued?
Ultragenyx Pharmaceutical Inc. (RARE) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 28.5×. The consensus analyst price target of $52.05 is 89% above the current price.
When does Ultragenyx Pharmaceutical Inc. report its next earnings?
Ultragenyx Pharmaceutical Inc.'s next earnings report is expected on approximately August 4, 2026.
What is Ultragenyx Pharmaceutical Inc.'s profit margin?
Ultragenyx Pharmaceutical Inc. has a net profit margin of -90.9%, indicating the company is currently operating at a net loss. Its gross margin stands at -28.1%, reflecting a more cost-intensive business model.
Is Ultragenyx Pharmaceutical Inc.'s revenue growing?
Ultragenyx Pharmaceutical Inc. is reporting revenue declining 2.2% year-over-year.